Stock IPN IPSEN
Add to a list
To use this feature you must be a member
Log inSign up

Ipsen Share Price

Equities

IPN

FR0010259150

Pharmaceuticals

Market Closed - Euronext Paris
Other stock markets
 10:06:37 10/12/2024 pm IST 		5-day change 1st Jan Change
110.30 EUR +1.01% Intraday chart for Ipsen +1.29% +2.22%
09/12 Nuvalent, Inc. Appoints Grant Bogle to Board of Directors CI
03/12 Ipsen: exclusive worldwide licensing agreement with Biomunex CF

Valuation: Ipsen

Capitalization 906.66Cr 952.57Cr 840.22Cr 747.32Cr 1.35TCr 81TCr 1.5TCr 10TCr 3.86TCr 33TCr 3.58TCr 3.5TCr 1,44900Cr P/E ratio 2024 *
14.7x
P/E ratio 2025 * 12.7x
Enterprise value 859.52Cr 903.04Cr 796.53Cr 708.47Cr 1.28TCr 77TCr 1.42TCr 9.92TCr 3.66TCr 31TCr 3.39TCr 3.32TCr 1,37300Cr EV / Sales 2024 *
2.46x
EV / Sales 2025 * 2.14x
Free-Float
41.56%
Yield 2024 *
1.09%
Yield 2025 * 1.12%
More valuation ratios * Estimated data

Chart: Ipsen

Dynamic Chart

Latest news: Ipsen

Nuvalent, Inc. Appoints Grant Bogle to Board of Directors 09/12 CI
Ipsen: exclusive worldwide licensing agreement with Biomunex 03/12 CF
Ipsen, Biomunex Sign Licensing Deal for Novel T Cell Engager BMX-502 03/12 MT
Trump-induced Pharma fears shouldn't be long-lived 19/11Alphavalue
Ipsen's Liver Disease Drug Reduces Patient Symptoms in Late-stage Studies 18/11 MT
Ipsen: data presented at CIFP and SAG 18/11 CF
Ipsen's Liver Disease Treatment Sustains Efficacy, Safety in Three-year Data 18/11 MT
Ipsen: presents latest data on Iqirvo 15/11 CF
Genfit: financing secured until the end of 2025 08/11 CF
Global markets live: Palantir soars, Boeing strike ends 05/11Our Logo
Musk on top of Wall Street 25/10Our Logo
CAC40: resists towards 7500, Wall Street widens its losses 23/10 CF
IPSEN : Slight Q3 beat + guidance upgrade 23/10Alphavalue
More news

Last Transcript: Ipsen

Logo Ipsen
Ipsen S.A., Nine Months 2024 Sales/ Trading Statement Call, Oct 23, 2024
23/10
More transcripts

Analysts' recommendations: Ipsen

IPSEN : Slight Q3 beat + guidance upgrade 23/10Alphavalue
Kepler Cheuvreux Downgrades Ipsen to Hold 14/10 MT
RBC Capital Upgrades Ipsen to Outperform, Lifts PT 16/09 MT
IPSEN : A good Q2 and guidance upgrade couldn’t impress investors 25/07Alphavalue
IPSEN : UBS remains positive ahead of quarterly results 26/06 CF
More recommendations

Press Releases: Ipsen

Ipsen : and Biomunex announce exclusive global licensing agreement for first in class MAIT cell engager in immuno oncology 03/12 PU
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology 03/12 GL
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology 03/12 AQ
Ipsen - Iqirvo data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus 18/11 AQ
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS 18/11 GL
More press releases

News in other languages: Ipsen

Wall Street vacille, l'Europe s'éparpille, la Chine scintille 10/12
Avis d'analystes du jour : L'Oréal, Unibail, TotalEnergies, Schneider, Nexans, Galderma, Amundi, Accor... 10/12
Ipsen rachète les droits mondiaux de l'anticancéreux BMX-502 à Biomunex 03/12
Le CAC40 fait de la résistance 03/12
Avis d'analystes du jour : Kering, Hermès, Michelin, UCB, Euroapi, Forvia, Galderma, Ipsen... 03/12
More news

Quotes and Performance

1 day+1.01%
1 week+1.29%
Current month+0.82%
3 months+0.27%
6 months-10.25%
Current year+2.22%
More quotes

Course Extremes

1 week
105.60
Extreme 105.6
113.30
1 month
105.50
Extreme 105.5
113.30
Current year
99.70
Extreme 99.7
126.70
1 year
99.70
Extreme 99.7
126.70
3 years
77.00
Extreme 77
130.70
5 years
34.20
Extreme 34.2
130.70
10 years
34.20
Extreme 34.2
155.95
More quotes

Managers and Directors: Ipsen

Director TitleAgeSince
David Loew CEO
 Chief Executive Officer 57 01/07/2020
Aymeric Le Chatelier CEO
 Chief Executive Officer 55 01/01/2020
Christelle Huguet CTO
 Chief Tech/Sci/R&D Officer 57 22/09/2023
Manager TitleAgeSince
Henri Beaufour BRD
 Director/Board Member 59 19/09/2005
Antoine Flochel BRD
 Director/Board Member 59 30/08/2005
Marc M. P. de Garidel CHM
 Chairman 66 22/11/2010
More insiders

ETFs: Ipsen

Name Weight AuM 1st Jan change Investor Rating
INDEXIQ FACTORS SUSTAINABLE EMU EQUITY UCITS ETF - EUR ETF IndexIQ Factors Sustainable EMU Equity UCITS ETF - EUR
0.83% 2 M€ +15.94%
INDEXIQ FACTORS SUSTAINABLE EUROPE EQUITY UCITS ETF - EUR ETF IndexIQ Factors Sustainable Europe Equity UCITS ETF - EUR
0.43% 177 M€ +10.64%
FRANKLIN LIBERTYQ EUROPEAN EQUITY UCITS ETF - EUR ETF Franklin LibertyQ European Equity UCITS ETF - EUR
0.31% 3 M€ +11.67% -
More ETFs: Ipsen

Other Pharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
IPSEN Stock Ipsen
+1.01%+1.29%+6.98%+19.89%949.66Cr
ELI LILLY AND COMPANY Stock Eli Lilly and Company
-0.50%-0.03%+33.70%+229.18%72TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+0.03%+0.86%+17.04%+108.44%49TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-0.25%-3.60%-3.36%-10.05%36TCr
ABBVIE INC. Stock AbbVie Inc.
-0.51%-3.36%+17.68%+41.50%31TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
-2.69%+0.39%-2.65%+38.62%26TCr
ROCHE HOLDING AG Stock Roche Holding AG
-1.32%-0.94%+0.20%-32.16%24TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
-1.78%-0.40%+3.85%+25.71%21TCr
NOVARTIS AG Stock Novartis AG
-0.69%-4.70%+4.77%+18.92%20TCr
AMGEN INC. Stock Amgen Inc.
-0.68%-0.85%+2.46%+29.72%15TCr
Average -0.50%-0.74%+8.07%+46.98% 29.6TCr
Weighted average by Cap. -0.48%-0.51%+13.05%+82.75%
See all sector performances

Financials

2024 *2025 *
Net sales 349.48Cr 367.18Cr 323.87Cr 288.06Cr 520Cr 31TCr 576.28Cr 4.03TCr 1.49TCr 13TCr 1.38TCr 1.35TCr 56TCr 369.83Cr 388.56Cr 342.73Cr 304.84Cr 550.28Cr 33TCr 609.84Cr 4.27TCr 1.58TCr 14TCr 1.46TCr 1.43TCr 59TCr
Net income 63Cr 66Cr 58Cr 52Cr 94Cr 5.62TCr 103.88Cr 726.93Cr 268.35Cr 2.31TCr 248.48Cr 243.12Cr 10TCr 73Cr 77Cr 68Cr 61Cr 109.26Cr 6.55TCr 121.09Cr 847.37Cr 312.81Cr 2.69TCr 289.65Cr 283.4Cr 12TCr
Net Debt -47Cr -50Cr -44Cr -39Cr -70Cr -4.2TCr -78Cr -544Cr -200.82Cr -1.73TCr -185.95Cr -181.94Cr -7.53TCr -116.05Cr -121.93Cr -107.55Cr -96Cr -172.68Cr -10TCr -191.37Cr -1.34TCr -494.36Cr -4.25TCr -457.75Cr -447.88Cr -19TCr
More financial data * Estimated data

Company Profile

Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Employees
5,325
Sector
Pharmaceuticals
Calendar
09/01/2025 - ODDO BHF Forum
More about the company

Quotes

Date Price Change Volume
10/24/10 110.30 € +1.01% 46,278
09/24/09 109.20 € +0.46% 75,564
06/24/06 108.70 € -1.72% 90,175
05/24/05 110.60 € +0.27% 75,670
04/24/04 110.30 € -0.72% 88,156

Real-time Euronext Paris, December 10, 2024 at 10:06 pm IST

More quotes

Income Statement and Estimates

income-statement-evolution-chart IPSEN More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
B+
surperformance-ratings-light-chart IPSENMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
110.30EUR
Average target price
128.62EUR
Spread / Average Target
+16.61%
Consensus
Profit revisions
estimates-change-chart IPSEN Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart IPSEN Company calendar
  1. Stock Market
  2. Equities
  3. IPN Stock
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition